banda transcan 2 2016ul

Advancing Liquid Biopsies for Monitoring and Personalized Treatment of Children with Neuroblastomas

Project Coordinator:
Hedi Deubzer (Germany), Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Pediatric Hematology/Oncology/SCT, Berlin

Project Partners:
Gudrun Schleiermacher (France), Institut Curie, Département d'Oncologie Pédiatrique et INSERM U830, Paris
Jaime Font de Mora (Spain), Hospital Universitario La Fe - HULAFE, Clinical and Translational Research on Cancer, Laboratory of Cellular and Molecular Biology, Valencia
Jo Vandesompele (Belgium), Ghent University, Department of Biomolecular Medicine, Gent
Sabine Taschner-Mandl (Austria), Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Department for Tumor Biology, Vienna
Gam Tytgat (Netherlands), Prinses Máxima Centrum voor kinderoncologie, Department of Solid Tumors, Utrecht

Project Abstract:
The embryonal tumor, neuroblastoma, accounts for 11% of all cancer-related deaths in children. Its heterogeneous tumor biology creates clinical variability spanning spontaneous regression to rapid metastasizing progression. Long-term survival of high-risk disease remains poor, with <40% overall survival after first-line treatment and <10% after relapse, despite considerable international efforts to improve treatment over the last decades. Liquid biopsies have the power to revolutionize clinical care for children with high-risk neuroblastoma by reflecting precise disease status at any time during treatment and care. Blood and bone marrow samples are a less invasive source of biomarkers for patient monitoring and therapeutic decision-making. The LIQUIDHOPE consortium combines internationally recognized experts in neuroblastoma pan-omics and computational discovery with leading pediatric oncologists to advance this emerging clinical paradigm change. LIQUIDHOPE aims to accelerate transfer of liquid biopsy approaches into the clinic within 3 parallel research arms designed to overcome current hurdles in (1) therapy response assessment, (2) minimal residual disease (MRD) monitoring and (3) actionable target identification, and define the best marker/analysis method or combination thereof for patient monitoring as its secondary aim. LIQUIDHOPE will apply targeted metabolomics; cfDNA whole-exome sequencing; cfDNA transcriptional start site and methylation profiling; unbiased total RNA profiling to monitor long noncoding and circular RNA disease markers; droplet digital PCR of DNA/RNA disease markers; automated multiple marker imaging and sophisticated bioinformatics. LIQUIDHOPE can identify and validate predictive markers for treatment response, MRD, relapse and treatment choice in blood/bone marrow surrogates to advance unique liquid biopsy-based innovations for patient monitoring and personalized treatment of children battling neuroblastoma.


(Project funded under JTC 2017)


 TRANSCAN-3 news:
twitter logoinkedin social media logo
 The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download



The TRANSCAN-3 newsletters are published at:

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter

All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 14 guests and no members online